Department of Burn and Plastic Surgery, The First Affiliated Hospital of Baotou Medical Collage, Inner Mongolia University of Science & Technology, Baotou, China.
Department of Rehabilitation, The First Affiliated Hospital of Baotou Medical Collage, Inner Mongolia University of Science & Technology, Baotou, China.
J Biomater Sci Polym Ed. 2023 Feb;34(2):200-216. doi: 10.1080/09205063.2022.2113290. Epub 2022 Aug 24.
Stable cartilage regeneration in immunocompetent animals remains a huge challenge, mainly ascribing to the implantation of tissue-engineered cartilage inevitably arousing inflammatory reactions, resulting in cartilage-specific extracellular matrix erosion, chondrogenic niche destruction, and chondrocyte deterioration. Herein, we developed an anti-inflammatory platform, namely, Cur/GelMA hydrogel, by loading a potent anti-inflammatory drug of curcumin (Cur) into gelatin methacryloyl (GelMA) hydrogel. The Cur/GelMA hydrogel exhibited satisfactory Cur release kinetics and exerted favorable anti-inflammatory effects when cocultured with lipopolysaccharide-induced RAW264.7 macrophages . Furthermore, the Cur/GelMA hydrogel showed gratifying biocompatibility and supported cartilage regeneration when colonized with rabbit- and goat-derived chondrocytes. In addition, the engineered cartilages in the Cur/GelMA hydrogel were able to maintain a cartilaginous phenotype and achieved stable cartilage regeneration when subcutaneously implanted in autologous rabbits and goats for 2 and 4 weeks compared to the GelMA hydrogel. Furthermore, our data revealed that the -generated cartilage in the Cur/GelMA group apparently alleviated the inflammatory reaction compared to its GelMA counterpart, suggesting that the locally released Cur endowed the Cur/GelMA hydrogel with potent anti-inflammatory capacity. This study provides a reliable anti-inflammatory platform for stable cartilage regeneration in immunocompetent animals, significantly advancing the clinical application of tissue-engineered cartilage.
在免疫功能正常的动物中实现稳定的软骨再生仍然是一个巨大的挑战,主要归因于组织工程软骨的植入不可避免地会引起炎症反应,导致软骨特异性细胞外基质的侵蚀、软骨生成龛的破坏和软骨细胞的恶化。在此,我们通过将一种有效的抗炎药物姜黄素(Cur)载入明胶甲基丙烯酰(GelMA)水凝胶中,开发了一种抗炎平台,即 Cur/GelMA 水凝胶。Cur/GelMA 水凝胶表现出令人满意的 Cur 释放动力学,并在与脂多糖诱导的 RAW264.7 巨噬细胞共培养时表现出良好的抗炎效果。此外,当与兔源性和 goat-derived 软骨细胞共培养时,Cur/GelMA 水凝胶表现出良好的生物相容性并支持软骨再生。此外,在自体兔和山羊体内皮下植入 2 和 4 周后,工程软骨在 Cur/GelMA 水凝胶中能够保持软骨表型并实现稳定的软骨再生,而在 GelMA 水凝胶中则不能。此外,我们的数据表明,与 GelMA 对照组相比,Cur/GelMA 组产生的软骨明显减轻了炎症反应,这表明局部释放的 Cur 使 Cur/GelMA 水凝胶具有强大的抗炎能力。这项研究为在免疫功能正常的动物中实现稳定的软骨再生提供了一个可靠的抗炎平台,极大地推进了组织工程软骨的临床应用。